Mirum Pharmaceuticals, Inc.
MIRM Healthcare Biotechnology
Mirum Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $521.3 million, up 54.7% from fiscal 2024. In the quarter to June 2026, revenue grew 37.9%, EPS fell 783.3%, free cash flow fell 681.5% and total debt rose 142.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
Follow MIRM
Mirum Pharmaceuticals, Inc. (MIRM) EV/Sales
As of 16 October 2026, Mirum Pharmaceuticals, Inc. (MIRM) trades at a EV/Sales of 8.7×. Over the past ten years it has ranged from 0.0× (March 2022) to 26.7× (April 2022); the current reading is higher than 71% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | 26.20% |
| FY2024 | 5.9× | (11.62%) |
| FY2023 | 6.7× | (19.70%) |
| FY2022 | 8.3× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 12.5× | 32.91% |
| Mar 2026 | 9.4× | 26.07% |
| Dec 2025 | 7.5× | (3.41%) |
| Sep 2025 | 7.7× | 30.84% |
| 17 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KOD Kodiak Sciences Inc. compare | n/m |
| ERAS Erasca, Inc. compare | n/m |
| IMVT Immunovant, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | 5.6× |
| TVTX Travere Therapeutics, Inc. compare | 8.0× |
| MIRM Mirum Pharmaceuticals, Inc. | 8.7× |
| COGT Cogent Biosciences, Inc. compare | 193× |
| CRSP CRISPR Therapeutics AG compare | 223× |
| CGON CG Oncology, Inc. compare | 684× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)